Clinical Trial

Proteinopathies Expression in Skin of Neurodegenerative Disorders

Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to compare the aggregation pattern of proteinopathies (alpha-synuclein, amyloid-beta, phosphorylated tau and transactive response DNA -binding protein 43 \[TDP43\]) in skin biopsies of patients with a neurodegenerative disease like Alzheimer's disease, frontotemporal lobe dementia, Parkinson's disease, atypical Parkinsonism, amyotrophic lateral sclerosis or normal pressure hydrocephalus. The main question it aims to answer is: * Is there a specific pattern of aggregation of proteinopathies in skin biopsies in each neurodegenerative disease in comparison to healthy control subjects? Skin biopsies will be analyzed using immunohistochemistry and immunofluorescence for detection of alpha-synuclein, amyloid-beta, phosphorylated tau and TAR DNA binding protein 43, and the aggregation patterns will be compared between patients with a neurodegenerative disease vs patient with normal pressure hydrocephalus vs healthy control subjects.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-29.
Trial Details
NCT Number NCT06528964
Lead Sponsor Universidad Autonoma de San Luis Potosí
Collaborators: Hospital Central "Dr. Ignacio Morones Prieto"
Conditions Alzheimer Disease, Frontotemporal Dementia, Parkinson Disease, Atypical Parkinsonism, Amyotrophic Lateral Sclerosis, Normal Pressure Hydrocephalus
Enrollment 40 participants
Start Date 2023-12-20
Primary Completion 2026-10-25 (estimated)
Study Completion 2026-11-01 (estimated)
Updated on ClinicalTrials.gov 2024-12-16